Test two hormone treatment combinations for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 19 or older.
- Your breast cancer has spread (metastatic) or is locally advanced and is hormone-receptor positive and HER2 negative.
- You have not had chemotherapy or hormone (endocrine) treatment for metastatic/advanced breast cancer before.
- You must not have used a CDK4/6 inhibitor before, and you must not have previously used fulvestrant or similar estrogen-targeting drugs (SERDs).
- Your body-blood and organ tests must meet limits (for example: enough white blood cells, platelets, hemoglobin; and acceptable kidney, liver, and bilirubin levels).
- If you could become pregnant, you must use reliable birth control during the study and for at least 6 months after stopping treatment; you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial compares two standard hormone therapy pill combinations for advanced breast cancer. One adds a higher dose of palbociclib plus hydroxychloroquine, while the other uses the standard palbociclib dose, to see if the higher dose is more effective.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.